Pharmaceutical

Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)

Tuesday, July 27, 2021 - 12:31pm

These data provide preliminary, but compelling evidence of eganelisibs potential to improve outcomes for patients with these two types of cancer.

Key Points: 
  • These data provide preliminary, but compelling evidence of eganelisibs potential to improve outcomes for patients with these two types of cancer.
  • These results are consistent with the results from MARIO-275, which show the similar translation of disease control into a meaningful survival benefit for patients.
  • For patients with TNBC, the potential to extend progression free survival, regardless of PD-L1 status, would be a transformational breakthrough.
  • MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.

Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update

Tuesday, July 27, 2021 - 12:30pm

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (Infinity or the Company), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2021 financial results and provided a corporate update.

Key Points: 
  • Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (Infinity or the Company), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2021 financial results and provided a corporate update.
  • Ms. Perkins continued, Were thrilled to have Dr. Peluso return to Infinity in the role of Chief Scientific Officer during this exciting time for Infinity.
  • Second Quarter 2021 Financial Results:
    At June 30, 2021, Infinity had total cash, cash equivalents and available-for-sale securities of $97.3 million, compared to $106.8 million at March 31, 2021.
  • Research and development expense for the second quarter of 2021 was $8.0 million, compared to $6.1 million in the same period in 2020.

Flora Growth to Partner with Avaria to Distribute Award-Winning Pain Cream Brand KaLaya Across LATAM & Produce Its CBD Formulations

Tuesday, July 27, 2021 - 12:05pm

Through the JV, Flora Growth will manage registration, sales, and distribution of KaLaya products in Colombia, Mexico, and other LATAM countries, while Avaria will supply finished product to the JV.

Key Points: 
  • Through the JV, Flora Growth will manage registration, sales, and distribution of KaLaya products in Colombia, Mexico, and other LATAM countries, while Avaria will supply finished product to the JV.
  • These products are expected to be distributed across LATAM using Flora Labs established distribution channels, with the aim of exporting to the U.S. market, where Avaria is currently launching the KaLaya brand.
  • Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale.
  • Avarias KaLaya pain cream brand has enjoyed strong success since inception, where it enjoys three consecutive years of triple digit growth through their industry leading Canadian e-commerce channels.

Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021

Tuesday, July 27, 2021 - 12:00pm

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.
  • In connection with the earnings release, Decipheras management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, August 3, 2021, to discuss the Companys financial results and provide a corporate update.
  • The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 9943767.
  • A webcast of the conference call will be available in the Events and Presentations page in the Investors section of the Companys website at https://investors.deciphera.com/events-presentations .

Antibe Therapeutics Provides July 2021 Corporate Update

Tuesday, July 27, 2021 - 12:00pm

Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.

Key Points: 
  • Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.
  • The program also combines several state-of-the-art aspects, including the hiring of leading providers of bioanalytic, quality control and data management services.
  • The latter will enable us to track and manage screening and enrollment in real-time, ensuring that the subject population matches trial criteria.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021

Tuesday, July 27, 2021 - 12:00pm

Patients with low-grade serous ovarian cancer urgently need better solutions due to low response rates and tolerability issues associated with other therapeutic approaches.

Key Points: 
  • Patients with low-grade serous ovarian cancer urgently need better solutions due to low response rates and tolerability issues associated with other therapeutic approaches.
  • The company-sponsored, registration-directed Phase 2 RAMP 201 study is well underway, with top-line results from the selection phase expected during the first half of 2022.
  • The FRAME study was expanded to include new cohorts in pancreatic cancer, KRAS mutant endometrioid cancer and KRAS-G12V NSCLC.
  • Verastem Oncology is also supporting an investigator-initiated Phase 2 trial evaluating VS-6766 with defactinib in patients with metastatic uveal melanoma.

IoT Pioneer Wiliot Secures $200 Million Investment Round Led by SoftBank Vision Fund 2

Tuesday, July 27, 2021 - 1:00pm

Wiliot, the Sensing as a Service company and Internet of Things (IoT) technology leader whose self-powered, stamp-sized computer is changing the relationship between manufacturers and their products, announced today it received $200 million in a Series C funding round led by SoftBank Vision Fund 2i (SoftBank).

Key Points: 
  • Wiliot, the Sensing as a Service company and Internet of Things (IoT) technology leader whose self-powered, stamp-sized computer is changing the relationship between manufacturers and their products, announced today it received $200 million in a Series C funding round led by SoftBank Vision Fund 2i (SoftBank).
  • Wiliot has created a vision of the future of AI-enabled IoT, and we are delighted that SoftBank is supporting us in making this future a reality, said Tal Tamir, Wiliots CEO.
  • We are pleased to play a part in helping Wiliot dramatically scale the ever-expanding application of IoT globally.
  • As part of the investment, Amit Lubovsky, Investor for SoftBank Investment Advisers, will join Wiliots Board of Directors.

IACTA Pharmaceuticals Appoints Yogesh Bahl as Chief Financial Officer and Eric Carter, M.D., Ph.D., as Chief Medical Officer

Tuesday, July 27, 2021 - 12:30pm

IACTA Pharmaceuticals, Inc. (IACTA), an innovation leader in ophthalmic therapeutics, today announced the appointment of Yogesh Bahl as Chief Financial Officer (CFO) and Eric Carter, M.D., Ph.D., as Chief Medical Officer (CMO).

Key Points: 
  • IACTA Pharmaceuticals, Inc. (IACTA), an innovation leader in ophthalmic therapeutics, today announced the appointment of Yogesh Bahl as Chief Financial Officer (CFO) and Eric Carter, M.D., Ph.D., as Chief Medical Officer (CMO).
  • All told, I believe IACTA has the right team in place to bring these much-needed ophthalmic innovations to the underserved patients who need them.
  • Yogesh Bahl brings over 25 years of pharmaceutical experience in strategy, finance, accounting, audit, and risk management.
  • Prior to Allergan, Dr. Carter served as Chief Science Officer, Head of R&D and Chief Medical Officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer in 2011.

Flor Americas Partners with Biosintex Laboratorios to Supply Cannabinoids for Argentina’s Pharmaceutical Market

Tuesday, July 27, 2021 - 12:17pm

Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.

Key Points: 
  • Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.
  • During the past 20 years, Biosintex Laboratorios has earned a reputation for developing and manufacturing world-class pharmaceuticals.
  • Recently, Biosintex Laboratorios received authorization to import CBD from a producer within Flor Americas network.
  • Biosintex Laboratorios is an Argentine pharmaceutical company that develops and manufactures medicinal products with more than 20 years of experience in the market.